natgillin/translations-raw huggingface dataset:
Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods.
Sistemski učinci mogu se pojaviti kod primjene svakog inhacijskog kortikosteroida, posebice kad su propisane visoke doze kroz dulja razdoblja.
systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g. beclomethasone) should be considered.
Treba razmotriti smanjenje doze glukokortikoida s pažljivim praćenjem lokalnih i sistemskih učinaka ili prebaciti bolesnika na terapiju glukokortikoidom koji nije supstrat za CYP3A4 (npr. beklometazon).
Systemic embolism
Sistemska embolija
Systemic exposure after intravenous administration as a constant rate infusion is dose proportional at doses up to and including 1.8 mg/m2.
Sistemska izloženost nakon intravenske primjene uz konstantnu brzinu infuzije proporcionalno je dozi, pri dozama do i uključujući 1,8 mg/m2.
Systemic exposure following inhalation of TOBI Podhaler is very low, however TOBI Podhaler should not be used during pregnancy unless clearly necessary, i.e. when the benefits to the mother outweigh the risks to the foetus.
Sistemska izloženost nakon inahalacije TOBI Podhalera vrlo je niska, međutim TOBI Podhaler se ne smije koristiti tijekom trudnoće osim ako to nije neophodno, tj. kada koristi za majku premašuju rizike za plod.
Systemic exposure from topical application of tacrolimus ointment is low (<1.0 ng/ml) and is unlikely to be affected by concomitant use of substances known to be inhibitors of CYP3A4.
Sistemska izloženost nakon topikalne primjene takrolimus masti je niska (<1,0 ng/ml) i na nju najvjerojatnije neće utjecati istovremena primjena tvari za koje se zna da inhibiraju CYP3A4.
Systemic exposure of regorafenib at steady-state increases dose proportionally up to 60 mg and less than proportionally at doses greater than 60 mg.
Sistemska izloženost regorafenibu u stanju dinamičke ravnoteže proporcionalno se povećava pri dozama do 60 mg, a manje proporcionalno pri dozama višima od 60 mg.
Systemic exposure to abiraterone after a single oral 1,000 mg dose increased by approximately 11% and 260% in subjects with mild and moderate pre-existing hepatic impairment, respectively.
Sustavna izloženost abirateronu nakon pojedinačne peroralne doze od 1000 mg povećala se za približno 11% u ispitanika s postojećim blagim te za približno 260% u ispitanika s postojećim umjerenim oštećenjem jetre.
Systemic exposure to ceritinib is increased when administered with food.
Sistemska izloženost ceritinibu povećava se kada se on primjenjuje uz hranu.
Systemic exposure to indacaterol increased with increasing (delivered) dose (120 µg to 480 µg) in a dose proportional manner.
Sistemska izloženost indakaterolu povećala se s povećanom (isporučenom) dozom (120 µg do 480 µg) proporcionalno dozi.
Systemic exposure to medicinal products metabolised by CYP2B6 may be decreased when co-administered with CRESEMBA.
Sistemska izloţenost lijekovima koji se metaboliziraju putem CYP2B6 moţe se smanjiti kada se primjenjuju istodobno s lijekom CRESEMBA.
Systemic exposure to stiripentol increases markedly compared to dose proportionality.
Sistemska izloženost stiripentolu se značajno povećava u usporedbi s razmjerom doze.
Systemic exposures (AUC) of trastuzumab emtansine at Cycle 1 in patients with mild and moderate hepatic impairment were approximately 38% and 67% lower than that of patients with normal hepatic function, respectively.
Sistemska izloženost trastuzumab emtanzinu (AUC) u 1. ciklusu bila je približno 38% niža u bolesnika s blagim i približno 67% niža u bolesnika s umjerenim oštećenjem jetre u odnosu na bolesnike s normalnom jetrenom funkcijom.
Systemic exposures after a single dose of sunitinib were similar in subjects with mild or moderate (Child-Pugh class A and B) hepatic impairment compared to subjects with normal hepatic function.
Sustavna izloženost nakon jedne doze sunitiniba bila je podjednaka u ispitanika s blagim ili umjerenim oštećenjem jetre (Child- Pugh stadij A i B) i u ispitanika s normalnom jetrenom funkcijom.
Systemic exposures after a single dose of sunitinib were similar in subjects with severe renal impairment (CLcr <30 ml/min) compared to subjects with normal renal function (CLcr >80 ml/min).
Sustavna izloženost nakon jedne doze sunitiniba bila je podjednaka u ispitanika s teškim oštećenjem bubrežne funkcije (CLcr <30 ml/min) i ispitanika s normalnom bubrežnom funkcijom (CLcr >80 ml/min).
Systemic exposures exceeded human therapeutic exposures after inhalation by factors of more than 10 (Cmax, cumulative AUC).
Sistemske izloženosti premašile su za više od 10 puta terapijske izloženosti u ljudi nakon inhalacije (Cmax, kumulativni AUC).
systemic exposures of
povećati sistemsku izloženost flutikazonu.
Systemic hypersensitivity reactions
sistemske reakcije preosjetljivosti
Systemic hypersensitivity reactions may include urticaria, chest tightness, dyspnoea, allergic dermatitis and pruritus.
Sistemske reakcije preosjetljivosti mogu uključivati urtikariju, pritisak u prsima, dispneju, alergijski dermatitis i svrbež.
Systemic infection or sepsis
Sistemska infekcija ili sepsa
Systemic Inflammatory Response Syndrome (SIRS)
Sindrom sistemskog upalnog odgovora
Systemic inflammatory response syndrome (SIRS) or capillary leak syndrome
Sindrom sistemskog upalnog odgovora (SIRS) ili sindrom povećane propusnosti kapilara
Systemic lidocaine
Sistemski lidokain
systemic lidocaine, quinidine, or
sistemskog lidokaina, kinidina ili
Systemic lupus erythematosus
istemski eritemski lupus
systemic lupus erythematosus
istemski lupus eritematosus
Systemic lupus erythematosus (also called “lupus” or “SLE”) a disease where the body’s immune system attacks the body.
Sistemski lupus eritematozus (također zvan «lupus» ili «SLE»), bolest u kojoj imunološki sustav napada tijelo.
Systemic lupus erythematosus (SLE)
sistemski eritemski lupus (SLE)
Systemic lupus erythematosus (SLE).
Sistemski eritemski lupus (SLE).
systemic lupus erythematosus, muscle weakness, arthritis
sistemski eritematozni lupus, slabost mišića, artritis
Systemic safety profile of IDflu is similar to the comparator vaccine, adjuvanted or non-adjuvanted, administered intramuscularly.
Sistemski sigurnosni profil IDflu-a sličan je onome kod komparativnog, adjuvantiranog ili neadjuvantiranog cjepivaprimjenjenog intramuskularno.
Systemic safety profile of INTANZA is similar to the comparator vaccine, adjuvanted or non- adjuvanted, administered intramuscularly.
Sistemski sigurnosni profil cjepiva INTANZA sličan je onome kod komparativnog, adjuvantiranog ili neadjuvantiranog cjepivaprimjenjenog intramuskularno.
Systemic sclerosis with digital ulcer disease
Sistemska skleroza s bolešću ulceracije prstiju
Systemic sclerosis with ongoing digital ulcer disease
Sistemska skleroza s aktivnom bolešću ulceracija prstiju
Systemically administered corticosteroids may cause polyuria, polydipsia and polyphagia, particularly during the early stages of therapy.
Sustavna primjena kortikosteroida može uzrokovati poliuriju, polidipsiju i polifagiju, posebice tijekom ranijih stadija terapije.
systolic blood pressure at entry > 160 mmHg
sistolički krvni tlak na početku liječenja > 160 mmHg
Systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg
Sistolički krvni tlak ≥160 mmHg ili dijastolički krvni tlak ≥100 mmHg
Systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg
Sistolički KT ≥160 mmHg ili dijastolički KT ≥100 mmHg
Sächsisches Serumwerk Dresden Branch of GlaxoSmithKline Biologicals Zirkustraße 40, D-01069 Dresden Germany
Sächsisches Serumwerk Dresden Podružnica GlaxoSmithKline Biologicals Zirkustraße 40, D-01069 Dresden Njemačka
Sími: + 354 540 8000 Puh/Tel: +358 (0)9 43 00 40
Sími: + 354 540 8000 Tel: + 421 2 3355 5500
Sími: +(44) 1323 501 111.
Sími: +358 20 180 5900
Sími: +354 530 3700
GlaxoSmithKline (Ireland) Ltd Tel: + 353 (0)1 4955000
Sími: +354 550 3300
Slovenská republika
Sími: +354-535 7000
Sími: +354 535 7000
Sími: +358 20 180 5900
Sími: +358 20 180 5900.
Sími: +358 9 180 452 5900
Sími: +(44) 1323 501 111.
T cell proliferative and γIFN ELISPOT responses to PAP and PAP-GM-CSF were observed in cells collected from peripheral blood of patients through the follow-up period in the Provenge treatment group but not in controls.
Proliferacija T stanica i stvaranje γIFN izmjereno ELISPOT testom kao odgovor na PAP i PAP-GM-CSF zabilježeni su u stanicama prikupljenim iz periferne krvi bolesnika kroz razdoblje praćenja u terapijskoj skupini Provenge, ali ne i u kontrolnim skupinama.
T cells must be activated before they work.
T–stanice moraju se aktivirati prije nego što počnu djelovati.
T cells must be ‘activated’ before they work.
T stanice moraju se „aktivirati” prije nego što počnu djelovati.
T-cells and immunoglobulin-secreting cells is enhanced, monocytes/macrophages are activated for killing of tumour cells, granulocytes are activated to display enhanced phagocytic activity, respiratory burst and degranulation, and adherence to endothelium.
T-stanica i stanica koje izlučuju imunoglobulin, monociti/makrofazi se usmjeravaju na uništavanje tumorskih stanica, granulociti se aktiviraju i pokazuju pojačanu fagocitnu aktivnost, respiratorni prasak i degranulaciju te adheziju na endotel.
T-lymphocyte (x106/l)
T-limfociti (x 106/l)
T-wave inversion
Inverzija T-vala
T. colubriformis
T. vitrinus
T. davtiani* Trichostrongylus axei*
Teladorsagia circumcincta
T/LAIV’s efficacy data in the paediatric population consist of 9 controlled studies comprising over 20,000 infants and toddlers, children and adolescents, conducted during 7 influenza seasons.
Podaci o djelotvornosti T/LAIV cjepiva prikupljeni su u 9 kontroliranih ispitivanja provedenih na više od 20 000 dojenčadi, male djece, djece i adolescenata tijekom 7 sezona influence.
t1/2 (hour)
Tmax (sati)
t1/2 (hr) mean (S.D.), range
t1/2 (hr) srednja vrijednost (S.D.), raspon
t1/2 effective
t1/2 efektivni
t1/2, hours
t½, sati
t1/2, minute§
t1/2, minuta§
T12(DS)/PR
T12/PR
T12/P(2a)R48: INCIVO for 12 weeks in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks T12/P(2b)R48: INCIVO for 12 weeks in combination with peginterferon alfa-2b and ribavirin for 24 or 48 weeks a 95% confidence interval for the difference was (-10.8, 12.1)
T12/PR48: INCIVO tijekom 12 tjedana nakon čega je slijedio placebo tijekom 4 tjedna, u kombinaciji s peginterferonom alfa-2a i ribavirinom tijekom 48 tjedana;
T12/PR48
T12(DS)/PR
T12/PR48: INCIVO for 12 weeks followed by placebo for 4 weeks, in combination with peginterferon alfa-2a and ribavirin for 48 weeks;
T12/PR24: INCIVO tijekom 12 tjedana uz peginterferon alfa-2a i ribavirin tijekom 24 tjedna;
T12/PR48: INCIVO for 12 weeks followed by placebo for 4 weeks, in combination with peginterferon alfa-2a and ribavirin for 48 weeks;
T12/PR48: INCIVO tijekom 12 tjedana nakon čega je slijedio placebo tijekom 4 tjedana, u kombinaciji peginterferonom alfa-2a i ribavirinom tijekom 48 tjedana;
T12/PR: INCIVO for 12 weeks with peginterferon alfa-2a and ribavirin for 24 or 48 weeks;
T12(b.i.d.)/PR: INCIVO 1125 mg dva puta na dan tijekom 12 tjedana s peginterferonom alfa-2a i ribavirinom tijekom 24 ili 48 tjedana;
T3 increase was reported in 1 (0.8%) sunitinib subject and no capecitabine subjects.
Povećanje T3 je prijavljeno kod 1 (0,8%) bolesnika na sunitinibu i niti jedan na capecitinib bolesnika.
T4 increase was reported in 2 (0.8%) sunitinib subjects and 1 (0.4%) capecitabine subject.
Povećanje T4 je prijavljeno kod 2 (0,8%) bolesnika na sunitinibu i 1 (0,4%) na capecitabinu.
Table 1 - Adverse reactions reported in clinical trials
Tablica 1 - Nuspojave prijavljene u kliničkim ispitivanjima
Table 1 - Adverse reactions reported in patients treated with the ZALTRAP/FOLFIRI regimen from the MCRC study
Tablica 1 - Nuspojave prijavljene u bolesnika liječenih protokolom ZALTRAP/FOLFIRI u ispitivanju MKRK-a
Table 1 - Dose modification table for ALIMTA (as single agent or in combination) and cisplatin – Haematologic toxicities
Tablica 1 - Tablica za prilagodbu doze lijeka ALIMTA (u monoterapiji ili u kombinaciji) i cisplatina - hematološka toksičnost
Table 1 - Dose modification table for ALIMTA (as single agent or in combination) and cisplatin –Haematologic toxicities
Tablica 1 - Tablica za prilagodbu doze lijeka ALIMTA (u monoterapiji ili u kombinaciji) i cisplatina - hematološka toksičnost
Table 1 - Dose modification table for CIAMBRA (as single agent or in combination) and cisplatin – Haematologic toxicities
Tablica 1 – Tablica za prilagodbu doze lijeka CIAMBRA (u monoterapiji ili u kombinaciji) i cisplatina – hematološka toksičnost
Table 1 - Dose modification table for pemetrexed (as single agent or in combination) and cisplatin – Haematologic toxicities
Tablica 1 - Tablica za prilagodbu doze pemetrekseda (u monoterapiji ili u kombinaciji) i cisplatina - hematološka toksičnost
Table 1 - Dose modification table for Pemetrexed Accord (as single agent or in combination) and cisplatin – Haematologic toxicities
Tablica 1 - Tablica za prilagodbu doze lijeka Pemetrexed Accord (u monoterapiji ili u kombinaciji) i cisplatina - hematološka toksičnost
Table 1 - Dose modification table for Pemetrexed Lilly (as single agent or in combination) and cisplatin – Haematologic toxicities
Tablica 1 – Tablica za prilagodbu doze lijeka Pemetrexed Lilly (u monoterapiji ili u kombinaciji) i cisplatina – hematološka toksičnost
Table 1 - Dose modification table for Pemetrexed lilly (as single agent or in combination) and cisplatin –Haematologic toxicities
Tablica 1 – Tablica za prilagodbu doze lijeka Pemetrexed Lilly (u monoterapiji ili u kombinaciji) i cisplatina – hematološka toksičnost
Table 1 - Main Results ( for the approved dose, ITT population)
Tablica1- Glavni rezultati (za odobrenu dozu, ITT populacija)
Table 1 - Recommended dose modifications for adverse reaction in patients treated with cabazitaxel
Tablica 1. – Preporučene prilagodbe doze u slučaju nuspojava u bolesnika liječenih kabazitakselom
Table 1 - Results of primary and key secondary endpoints in HZA106827 and HZA106829
Tablica 1 – Rezultati primarnih i ključnih sekundarnih mjera ishoda u ispitivanjima HZA106827 i HZA106829
Table 1 - Starting dose calculation according to body surface area (BSA)
Tablica 1 – Izračun početne doze prema površini tijela (PT)
TABLE 1 : SAMARIUM-153 PRINCIPAL RADIATION EMISSION DATA
TABLICA 1: PODACI O GLAVNIM VRSTAMA EMISIJE ZRAČENJA KOJE NASTAJU RASPADOM SAMARIJA-153
Table 1 ADRs occurring in patients treated with Erivedge in clinical trials
Tablica 1 Nuspojave koje se javljaju u bolesnika liječenih lijekom Erivedge u kliničkim ispitivanjima
Table 1 Adverse drug reactions detected in clinical trials
Tablica 1 Nuspojave na lijek otkrivene u kliničkim ispitivanjima
Table 1 Adverse Drug Reactions Reported for Oral Administration of Bondronat
Tablica 1 Nuspojave prijavljene uz peroralnu primjenu lijeka Bondronat
Table 1 Adverse Drug Reactions Reported for Oral Administration of Ibandronate
Tablica 1 Nuspojave prijavljene uz peroralnu primjenu ibandronata
Table 1 Adverse Drug Reactions Reported for Oral Administration of Ibandronic acid
Tablica 1 Nuspojave lijeka prijavljene uz peroralnu primjenu ibandronatne kiseline
Table 1 Adverse Drug Reactions Reported for Oral Administration of Ibandronic Acid
Tablica 1 Nuspojave prijavljene uz peroralnu primjenu Ibandronatne kiseline
Table 1 Adverse reactions by MedDRA System Organ Classification
Tablica 1 Nuspojave prema MedDRA klasifikaciji organskih sustava
Table 1 Adverse reactions by preferred term for pasireotide intramuscular use in the two phase III studies in acromegaly patients
Tablica 1 Nuspojave za pasireotid koji se primjenjuje intramuskularno u dva ispitivanja faze III na bolesnicima s akromegalijom prema preporučenom izrazu
Table 1 Adverse reactions by SOC and MedDRA frequency
Tablica 1 Nuspojave prema klasifikaciji organskih sustava i učestalosti prema MedDRA definiciji
Table 1 Adverse reactions by System Organ Class (SOC) and frequency
Tablica 1 Nuspojave prema klasifikaciji organskih sustava i učestalosti
Table 1 Adverse reactions from clinical studies and post-marketing reports
Tablica 1 Nuspojave iz kliničkih ispitivanja i postmarketinških izvješća
Table 1 Adverse reactions in clinical studies and from post-marketing experience
Tablica 1 Nuspojave u kliničkim ispitivanjima i nakon stavljanja lijeka u promet
Table 1 Adverse reactions in clinical trials and postmarketing
Tablica 1 Nuspojave u kliničkim istraživanjima i u postmarketinškom praćenju
Table 1 Adverse reactions in clinical trials and postmarketing
Tablica 2 Nuspojave u kliničkim istraživanjima i u postmarketinškom praćenju
Table 1 Adverse reactions in studies investigating oseltamivir for treatment and prevention of influenza in adults and adolescents or through post-marketing surveillance
Tablica 1 Nuspojave zabilježene u ispitivanjima liječenja i prevencije gripe oseltamivirom u odraslih i adolescenata ili nakon stavljanja lijeka u promet
Table 1 Adverse reactions in the phase III study in Cushing’s disease patients
Tablica 1 Nuspojave u ispitivanju faze III na bolesnicima s Cushingovom bolešću
Table 1 Adverse Reactions Reported for Intravenous Administration of Bondronat
Tablica 1 Nuspojave prijavljene kod intravenske primjene lijeka Bondronat
Table 1 Adverse Reactions Reported for Intravenous Administration of Ibandronic Acid
Tablica 1 Nuspojave lijeka prijavljene kod intravenske primjene ibandronatne kiseline
Table 1 Adverse Reactions Reported for Intravenous Administration of Ibandronic Acid
Tablica 1 Nuspojave prijavljene kod intravenske primjene ibandronatne kiseline
Table 1 Adverse reactions reported from patients receiving catumaxomab treatment
Tablica 1 Nuspojave u bolesnika koji su primali liječenje katumaksomabom
Table 1 Adverse reactions reported in patients who received Jentadueto (frequencies identified from pooled analysis of placebo-controlled studies) in clinical trial and from post-marketing experience
Tablica 1 Nuspojave prijavljene u bolesnika koji su primali (učestalosti utvrđene iz združene analize placebom kontroliranih ispitivanja) u kliničkim ispitivanjima te iz iskustva nakon stavljanja lijeka u promet
Table 1 Adverse reactions reported in patients who received linagliptin 5 mg daily as monotherapy or as add-on therapies (frequencies identified from pooled analysis of placebo-controlled studies) in clinical trial and from post-marketing experience
Tablica 1 Nuspojave prijavljene kod bolesnika koji su primali linagliptin 5 mg dnevno u obliku monoterapije ili kao dodatnu terapiju (učestalosti prepoznate iz združene analize placebom kontroliranih ispitivanja) u sklopu kliničkog ispitivanja i iz iskustava stečenih nakon stavljanja lijeka na tržište
Table 1 Adverse reactions reported in patients with advanced malignancies involving bone or with giant cell tumour of bone
Tablica 1 Nuspojave zabilježene u bolesnika s uznapredovalim malignim bolestima koje zahvaćaju kosti ili s gigantocelularnim tumorom kosti
Table 1 Adverse reactions reported in patients with osteoporosis and breast or prostate cancer patients receiving hormone ablation
Tablica 1: Nuspojave zabilježene u bolesnika s osteoporozom i u bolesnika s rakom dojke ili prostate koji su primali hormonsku ablacijsku terapiju
Table 1 Adverse reactions reported in phase 3 controlled studies
Tablica 1 Nuspojave prijavljene u kontroliranim ispitivanjima faze 3
Table 1 Adverse reactions reported in placebo-controlled studies
Tablica 1: Nuspojave prijavljene u placebom kontroliranim ispitivanjima
Table 1 Adverse reactions reported in the pooled 6-month database
Tablica 1 Nuspojave prijavljene u bazi objedinjenih podataka za 6 mjeseci
Table 1 Adverse reactions requiring dose modification of lenvatinib
Tablica 1 Nuspojave koje zahtijevaju promjenu doze lenvatiniba
Table 1 Analysis of coefficient of fat absorption over 72 hours (CFA72h) – completers population (study : PR005)
Tablica 1 Analiza koeficijenta apsorpcije masti tijekom 72 sata (CFA-72 h) – Populacija koja je sudjelovala u ispitivanju do kraja (Ispitivanje PR-005)
Table 1 below provides daily doses of Emtriva 10 mg/ml oral solution according to the degree of renal insufficiency.
U tablici 1 u nastavku navedene su dnevne doze Emtriva 10 mg/ml oralne otopine prema stupnju insuficijencije bubrega.
Table 1 contains very common (≥ 1/10), common (≥ 1/100, < 1/10); uncommon (≥ 1/1000, < 1/100); rare (≥ 1/10,000, < 1/1,000) adverse reactions which occurred in clinical trials and a post- marketing surveillance survey.
Tablica 1 sadrži vrlo često (≥ 1/10), često (≥ 1/100, <1/10), manje često (≥ 1/1000, <1/100); i rijetko (≥ 1/10,000, <1/1,000) nuspojave koje su se javile u kliničkim ispitivanjima i izvješćima nakon stavljanja lijeka u promet.
Table 1 Day-to-day variability within-patients in glucose-lowering-effect of Tresiba and insulin glargine at steady-state in patients with type 1 diabetes mellitus
Tablica 1 Intraindividualna varijabilnost dan za danom učinka lijeka Tresiba i glargin inzulina na snižavanje razine glukoze u stanju dinamičke ravnoteže, u bolesnika sa šećernom bolešću tipa 1
Table 1 displays the adverse reactions reported in 1,670 patients with Alzheimer’s dementia treated in randomised, double-blind, placebo and active-controlled clinical studies with Exelon transdermal patches for a duration of 24-48 weeks and from post-marketing data.
Tablica 1 prikazuje nuspojave zabilježene u 1670 bolesnika s Alzheimerovom demencijom liječenih u randomiziranim, dvostruko slijepim, placebom i aktivno kontroliranim kliničkim ispitivanjima s Exelon transdermalnim flasterom u trajanju od 24-48 tjedana te iz podataka nakon stavljanja lijeka u promet.
Table 1 displays the adverse reactions reported in 1,670 patients with Alzheimer’s dementia treated in randomised, double-blind, placebo and active-controlled clinical studies with Prometax transdermal patches for a duration of 24-48 weeks and from post-marketing data.
Tablica 1 prikazuje nuspojave zabilježene u 1670 bolesnika s Alzheimerovom demencijom liječenih u randomiziranim, dvostruko slijepim, placebom i aktivno kontroliranim kliničkim ispitivanjima s Prometax transdermalnim flasterom u trajanju od 24-48 tjedana te iz podataka nakon stavljanja lijeka u promet.
Table 1 displays the adverse reactions reported in 854 patients with Alzheimer’s dementia treated in randomised, double-blind, placebo and active-controlled clinical studies with rivastigmine transdermal patches for a duration of 24-48 weeks and from post-marketing data.
Tablica 1 prikazuje nuspojave zabilježene u 854 bolesnika s Alzheimerovom demencijom liječenih u randomiziranim, dvostruko slijepim, placebom i aktivno kontroliranim kliničkim ispitivanjima s transdermalnim flasterom s rivastigminom u trajanju od 24-48 tjedana te iz podataka nakon stavljanja lijeka u promet.
Table 1 displays the frequency of adverse reactions.
Tabela 1 pokazuje učestalost nuspojava.
Table 1 Dose adjustments for neutropenia and thrombocytopenia
Tablica 1 Prilagođavanje doze zbog neutropenije i trombocitopenije
Table 1 Dose reduction schedule
Tablica 1 Raspored smanjenja doze
Table 1 Dosing for combination therapy*
Tablica 1 Doziranje u kombiniranoj terapiji
Table 1 Frequencies of adverse reactions
Tablica 1 Učestalosti nuspojava
Table 1 Frequency category of adverse drug reactions reported in the phase 3 studies (COMFORT-I, COMFORT-II, RESPONSE)
Tablica 1 Kategorija učestalosti nuspojava na lijek prijavljenih u ispitivanjima faze 3 (COMFROT-I, COMFORT-II, RESPONSE)
Table 1 Frequency of adverse reactions by system organ class
Tablica 1 Učestalost nuspojava prema organskim sustavima
Table 1 Frequency of adverse reactions by system organ class from clinical trials and postmarketing experience
Tablica 1 Učestalost nuspojava prema klasifikaciji organskih sustava iz kliničkih ispitivanja i iskustva nakon stavljanja lijeka u promet
Table 1 Frequency of adverse reactons by system organ class from clinical trials and postmarketing experience
Tablica 1 Učestalost nuspojava prema klasifikaciji organskih sustava iz kliničkih ispitivanja i iskustva nakon stavljanja lijeka u promet
Table 1 gives the adverse reactions observed from clinical trials in 71 patients (age 1 day to 66 years).
Tablica 1 prikazuje nuspojave opažene u kliničkim ispitivanjima u 71 bolesnika (u dobi od 1 dana do 66 godina).